Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ALPHA3 Enrollment Momentum Continues, Supported by Expanding Trial Network, Increased MRD Screening, and Brisk Enrollment in Asia-PacificNext ALPHA3 Clinical Update Anticipated in Mid-2027, with Trial Enrollment Completion Expected by Year-End 2027Appointed Cell Therapy Commercialization Veteran Rocio Manghani, MPH, as Vice President, Market Access, Evidence & StrategyInvestor Event at ASH to Focus on Cema-cel’s Potential to Overcome Barrie ...